A Study of LY3154207 in Healthy Participants

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study involves single doses of LY3154207 and will evaluate the effects of LY3154207 on the body. There will be 3 parts to this study.

Part A will test single increasing doses of LY3154207 and will last approximately 7 weeks for each participant. Each participant will receive two doses of LY3154207, if part A is completed.

Part B will test a single dose of LY3154207 and will last approximately 5 weeks for each participant. Part B includes collecting fluid from the spinal column to measure levels of LY3154207.

Part C will include a single dose of LY3154207 given alone and then a second dose given along with itraconazole to look for change in LY3154207 levels. Part C will last about 3 weeks for each participant.

Participants may only enroll in 1 of the 3 parts of the study.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Hydroxyitraconazole; Itraconazole

Criteria

Inclusion Criteria:

• Overtly healthy males or females, as determined by medical history and physical examination

• Female participants not of child-bearing potential

• Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures

• Have given written informed consent

• Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/m^2)

Exclusion Criteria:

• Part B only: Have medical or surgical conditions in which lumbar puncture is contraindicated

• Part C only: Have known allergy or contraindications to itraconazole